Category Archives: Global News Feed


Stem Cell Clinic > Global News Feed

Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to Appeal

By Global News Feed

CORAL GABLES, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the federal judge handling Catalyst's case against the FDA has adopted the previously reported Report and Recommendation of the Magistrate Judge, granted summary judgment in favor of the FDA and Jacobus, and dismissed Catalyst's case. Catalyst is currently reviewing the District Judge's decision, which it believes to be erroneous, and intends to appeal the result to the Eleventh Circuit Court of Appeals.

Visit link:
Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to Appeal

Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial

By Global News Feed

Mechelen, Belgium; 29 September 2020, 22.01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of a first patient in their psoriasis trial, one of three patient trials currently recruiting to evaluate efficacy and safety of Toledo compound GLPG3970. Furthermore, Galapagos plans to unveil the novel Toledo target class and share GLPG3970 Phase 1 data at its inaugural Toledo Roundtable to be held virtually on 27 October 2020.

Original post:
Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial

Caladrius Biosciences to Present at the BIO Investor Forum Digital

By Global News Feed

BASKING RIDGE, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Executive Officer, David J. Mazzo, Ph.D., will present a company overview at the BIO Investor Forum, being held virtually on October 13-15, 2020. This presentation will be available on demand for BIO Investor attendees.

Original post:
Caladrius Biosciences to Present at the BIO Investor Forum Digital

Akouos Announces Key Leadership Appointments

By Global News Feed

BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced the appointment of Sachiyo Minegishi as chief financial officer, effective today. In addition, the company announced that Jennifer Wellman has been promoted to chief operating officer, from her prior role as senior vice president of regulatory and quality.

Read the rest here:
Akouos Announces Key Leadership Appointments

Orphazyme closes its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private…

By Global News Feed

Orphazyme A/SCompany announcement                                                                                         No. 59/2020                                                                                                           Company Registration No. 32266355

See the original post here:
Orphazyme closes its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private...

Prelude Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

By Global News Feed

WILMINGTON, Del., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its initial public offering of 9,573,750 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 1,248,750 additional shares of common stock, at a public offering price of $19.00 per share. The aggregate gross proceeds to Prelude Therapeutics from the offering were approximately $181.9 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Prelude Therapeutics.

See the rest here:
Prelude Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October…

By Global News Feed

NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company developing Natural Killer Cell Therapeutics, today announced that it will participate in three key conferences in October 2020.

See more here:
Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October...

→←